Form 4: Zymeworks CSO Reports Significant Equity Activity

Zymeworks' Chief Scientific Officer, Paul Andrew Moore, reported a series of equity transactions including RSU vesting, tax-related stock sales, and new grants of stock options, restricted stock units, and performance stock units.

Summary

• Paul Andrew Moore, Chief Scientific Officer of Zymeworks Inc. (ZYME), reported multiple equity transactions on January 12, 2026.
• Acquired 17,666 shares of common stock upon the vesting of restricted stock units (RSUs) granted on January 10, 2025, with a deemed acquisition price of $0.00 per share.
• Disposed of 9,560 shares of common stock at a weighted average price of $22.6735 per share to cover tax withholding obligations and other applicable fees related to the RSU vesting. This was a mandatory 'sell to cover' transaction, not a discretionary sale.
• Received a grant of 70,000 stock options with an exercise price of $23.16 per share, vesting 25% on the first anniversary of the grant date and the remainder in 36 equal monthly installments thereafter, expiring on January 11, 2036.
• Received a grant of 47,000 restricted stock units (RSUs), which vest in four equal annual installments beginning on the first anniversary of the grant date.
• Received a grant of 66,000 performance stock units (PSUs), representing the maximum number that may be earned. These PSUs are contingent on achieving certain cumulative total shareholder return (TSR) goals over a three-year performance period ending on January 12, 2029, with a target of 33,000 PSUs (50% to 200% may be earned).

Sentiment

Score: 7

Explanation: The transactions primarily involve the grant of new equity incentives (stock options, RSUs, PSUs) to a key executive, aligning their interests with long-term company performance. The sale of shares was non-discretionary and solely for tax withholding, which is a neutral event. The overall sentiment is positive due to the strong incentive alignment.

Positives

• The grant of 70,000 stock options, 47,000 restricted stock units, and up to 66,000 performance stock units aligns the Chief Scientific Officer's interests with long-term shareholder value creation.
• Performance Stock Units (PSUs) are tied to Total Shareholder Return (TSR) goals, directly linking executive compensation to the company's market performance over a three-year period.

Negatives

• The disposition of 9,560 shares, even if for tax purposes, reduces the Chief Scientific Officer's direct beneficial ownership of common stock.

Risks

• Vesting of performance stock units (PSUs) is contingent on the achievement of specific cumulative total shareholder return (TSR) goals over a three-year period ending January 12, 2029, and continued service, introducing performance and retention risk.
• The actual number of shares received from PSUs can range from 50% to 200% of the target number (33,000), depending on TSR achievement, creating uncertainty in the final compensation value.

Future Outlook

The equity grants, particularly the performance stock units tied to Total Shareholder Return, indicate a strategic focus on long-term executive incentive alignment with shareholder value creation over the next three years.

Industry Context

Equity compensation, including restricted stock units, performance stock units, and stock options, is a standard practice in the biotechnology sector. It is widely used to attract, retain, and incentivize key executives, aligning their financial interests with the company's long-term growth and shareholder value creation.

Comparison to Industry Standards

• Equity compensation, including RSUs, PSUs, and stock options, is a common practice in the biotechnology sector to incentivize executives and align their interests with long-term shareholder value creation.
• The structure of performance-based units tied to Total Shareholder Return (TSR) is a recognized best practice for executive compensation, often seen in companies like Amgen or Gilead Sciences, aiming to link executive rewards directly to market performance.

Related Party Transactions

• The equity grants (stock options, RSUs, PSUs) to the Chief Scientific Officer represent compensation transactions with a related party.

Stakeholder Impact

• Shareholders benefit from the increased alignment of the Chief Scientific Officer's financial interests with the company's long-term performance through significant equity grants.
• The Chief Scientific Officer receives substantial equity compensation, incentivizing continued service and performance.

Next Steps

• Continued vesting of the newly granted stock options and restricted stock units over their respective schedules.
• Achievement of Total Shareholder Return (TSR) goals for the performance stock units over the three-year period ending January 12, 2029.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation and a tax-related stock sale by a key executive. While the grants align management incentives with shareholder value, the filing does not contain new operational or financial performance data that would warrant a change in investment recommendation.

Keywords

Zymeworks, ZYME, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Performance Stock Units, Stock Options, Chief Scientific Officer, Biotechnology, TSR